ClinicalTrials.gg
CompletedNCT04362137RUXCOVIDUpdated Oct 11, 2021Results posted

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

A Phase 3 interventional study of Ruxolitinib and Placebo in Cytokine Storm (Covid-19), sponsored by Novartis Pharmaceuticals. Completed at 61 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Cytokine Release Syndrome with a site in United States — 11 open to participants now, 14 under way, 1 of them phase 3. Cytokine Release Syndrome · United States.

Enrollment
3rd of 46
432 · median 29
Started
2020
with 23 others
Phase 3
7 of 49
none open now
Registered
14th of 49
by date
Lead sponsor
2 of 49
Novartis Pharmaceuticals

Among the 49 studies in Cytokine Release Syndrome with a site in United States, this one is the 3rd largest by enrollment of the 46 interventional ones that give a count, is one of 24 that started in 2020, is one of 7 in phase 3, and was the 14th registered.

Cytokine Release Syndrome

163 studies on the registry are indexed under Cytokine Release Syndrome; 31 are open to participants now.

Browse Cytokine Release Syndrome studies →

Open to participants now

11 of the 49 studies in Cytokine Release Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Cytokine Release Syndrome studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Cytokine Release Syndrome with a site in United States, or all of them as a file.
02

Study summary

This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years with COVID-19 disease.

Read the detailed description

This was a Phase III, multicenter, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of ruxolitinib in patients aged ≥12 years with COVID-19 disease. The study enrolled patients to ruxolitinib or placebo, in addition to standard of care (SoC) per local practice. Patients who meet the inclusion/exclusion criteria were randomized in a 2:1 ratio to either oral ruxolitinib 5 mg twice daily + SoC or oral matching-image placebo + SoC for a total of 14 days. An additional 14 days of study drug could be given if in the opinion of the investigator the patient's clinical signs and symptoms did not improve, or worsen, and the potential benefit outweighed the potential risk.

The study included:

  • Screening period of 0-2 days.
  • Study period of 29 days (treatment of 14 days with possible extension of treatment to 28 days).

The primary objective was to evaluate the efficacy (as measured by a composite endpoint of proportion of patients who die, develop respiratory failure [require mechanical ventilation], or require intensive care unit care) of ruxolitinib + standard-of-care (SoC) therapy compared with placebo + SoC therapy, for the treatment of COVID-19 by Day 29.

03

Conditions studied

  • Cytokine Storm (Covid-19)

Keywords

  • COVID-19 pneumonia
  • cytokine release syndrome
  • SARS-COV-2
  • ruxolitinib
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient or guardian/health proxy must provide (and assent if applicable) before any study assessment is performed.

Male and female patients aged ≥ 12 years (or ≥ the lower age limit allowed by Health Authority and/or Ethics Committee/Institutional Review Board approvals).

Patients with coronavirus (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) test or another rapid test from the respiratory tract prior to randomization.

Patients currently hospitalized or will be hospitalized prior to randomization.

Patients, who meet at least one of the below criteria:

  • Pulmonary infiltrates (chest X ray or chest CT scan);
  • Respiratory frequency ≥ 30/min;
  • Requiring supplemental oxygen;
  • Oxygen saturation ≤ 94% on room air;
  • Arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2) \< 300mmHg (1mmHg=0.133kPa) (corrective formulation should be used for higher altitude regions (over 1000m).

Exclusion criteria

Exclusion Criteria:

History of to any drugs or metabolites of similar chemical classes as ruxolitinib.

Presence of severely impaired renal function defined by serum creatinine > 2 mg/dL (>176.8 μmol/L), or have estimated \< 30 ml/min measured or calculated by Cockroft Gault equation or calculated by the updated bedside Schwartz equation.

Suspected uncontrolled bacterial, fungal, viral, or other infection (besides COVID-19).

Currently intubated or intubated between screening and randomization. In intensive care unit (ICU) at time of randomization. Intubated or in ICU for COVID-19 disease prior to screening. Patients who are on anti-rejection, or immunomodulatory drugs (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra).

Unable to ingest tablets at randomization. Pregnant or nursing (lactating) women

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
432 participants (actual)

Study arms

  • Experimental
    Ruxolitinib 5 mg

    Ruxolitinib 5 mg tablets twice daily (b.i.d.) for 14 days with possible extension of treatment to 28 days

    Drug: Ruxolitinib

  • Placebo comparator
    Placebo

    Matching-image placebo for 14 days with possible extension of treatment to 28 days

    Drug: Placebo

Interventions

  • Ruxolitinib 5 mg tablets

    Also known as: INC424

  • DrugPlacebo

    Matching-image placebo

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care

    Efficacy is measured by a composite endpoint of proportion of patients who die, develop respiratory failure \[require mechanical ventilation\], or require intensive care unit \[ICU\] care for the treatment of COVID-19. Analyses are cumulative, thus analysis on Day 29 includes all events till that day. Patients who developed respiratory failure and/or required ICU at randomization are excluded from the analysis.

    Time frame: Day 1 - Day 29

Secondary outcomes

  1. Clinical Status

    Clinical status is measured with the 9-point ordinal scale. The scoring is: * Uninfected patients have a score 0 (no clinical or virological evidence of infection). * Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). * Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as peripheral oxygen saturation (SpO2) ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). * Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). * Patients who die have a score 8.

    Time frame: Baseline, Day 15, Day 29

  2. Percentage of Patients With at Least Two-point Improvement From Baseline in Clinical Status

    Percentage of patients with at least two points improvement in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.

    Time frame: Baseline, Day 15, Day 29

  3. Percentage of Patients With at Least One-point Improvement From Baseline in Clinical Status

    Percentage of patients with at least one point improvement in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.

    Time frame: Baseline, Day 15, Day 29

  4. Percentage of Patients With at Least One-point Deterioration From Baseline in Clinical Status

    Percentage of patients with at least one point deterioration in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.

    Time frame: Baseline, Day 15, Day 29

  5. Time to Improvement in Clinical Status

    Time to improvement in clinical status from baseline category to one less severe category of the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Median time to improvement is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study. Patients who did not achieve improvement and did not die are censored at their last clinical status assessment date.

    Time frame: 29 days

  6. Mean Change From Baseline in the Clinical Status

    Mean change from baseline in the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are excluded from the analysis. A negative change from baseline in the clinical status is a favorable outcome.

    Time frame: Baseline, Day 15, Day 29

  7. Mortality Rate

    Mortality rate is determined as the proportion of participants who died by study Day 15 and Day 29

    Time frame: Day 15, Day 29

  8. Proportion of Patients Requiring Mechanical Ventilation

    Proportion of patients requiring mechanical ventilation. Analyses are cumulative, thus analysis on Day 29 includes all events till that day. Patients who required mechanical ventilation at randomization are excluded from the analysis.

    Time frame: Day 1 - Day 29

  9. Duration of Hospitalization

    Duration of hospitalization is defined as time to hospital discharge. Median time to hospital discharge is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study. Patients who were not discharged and did not die are censored at their last assessment date.

    Time frame: 29 days

  10. Time to Hospital Discharge or to a NEWS2 Score of ≤2

    The time to hospital discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours whichever comes first. The NEWS2 is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst). Median time is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study.

    Time frame: 29 days

  11. Change From Baseline in NEWS2 Score

    The National Early Warning Score 2 (NEWS2) is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst). At each visit, only patients with a value at both baseline and the respective visit are included. A negative change from baseline in NEWS2 score is a favorable outcome.

    Time frame: Baseline, Days 3, 5, 8, 11, 15, and 29

  12. Change From Baseline in SpO2/FiO2 Ratio

    Change from baseline in peripheral oxygen saturation / fraction of inspired oxygen ratio (SpO2/FiO2 ratio). At each visit, only patients with a value at both baseline and the respective visit are included. A positive change from baseline in SpO2/FiO2 ratio is a favorable outcome.

    Time frame: Baseline, Day 15, Day 29

  13. Proportion of Patients With no Oxygen Therapy

    Proportion of patients with no oxygen therapy (defined as oxygen saturation ≥ 94% on room air) at Days 15 and 29. Analyses are cumulative, thus analysis on each day includes all events till that day. Patients with missing data at Day 15 and/or Day 29 are excluded from the analysis.

    Time frame: Day 15, Day 29

07

Results

Posted Jun 2, 2021

Participant flow

Participants took part in 61 investigative sites in 12 countries.

Participant flow — Overall Study
MilestoneRuxolitinib 5 mgPlacebo
Started287145
Safety set281143
Completed269139
Not completed186
Withdrew: Death93
Withdrew: Patient decision63
Withdrew: Adverse event10
Withdrew: Lost to follow-up10
Withdrew: Protocol deviation10

Outcome measures

PrimaryProportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care

Efficacy is measured by a composite endpoint of proportion of patients who die, develop respiratory failure \[require mechanical ventilation\], or require intensive care unit \[ICU\] care for the treatment of COVID-19. Analyses are cumulative, thus analysis on Day 29 includes all events till that day. Patients who developed respiratory failure and/or required ICU at randomization are excluded from the analysis.

Time frame:
Day 1 - Day 29
Reported as:
Count of participants · Participants
Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care
ParticipantsRuxolitinib 5 mgPlacebo
Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care3417
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.769 · Odds ratio (or): 0.91 · 95% CI 0.48 to 1.73Comparison is ruxolitinib 5 mg/placebo. An odds ratio \< 1 favors the ruxolitinib 5 mg arm
SecondaryClinical Status

Clinical status is measured with the 9-point ordinal scale. The scoring is: * Uninfected patients have a score 0 (no clinical or virological evidence of infection). * Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). * Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as peripheral oxygen saturation (SpO2) ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). * Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). * Patients who die have a score 8.

Time frame:
Baseline, Day 15, Day 29
Reported as:
Mean · score on scale
Clinical Status
score on scaleRuxolitinib 5 mgPlacebo
Baseline3.7 ± 0.563.7 ± 0.53
Day 151.8 ± 1.541.8 ± 1.41
Day 291.1 ± 1.611.0 ± 1.41
SecondaryPercentage of Patients With at Least Two-point Improvement From Baseline in Clinical Status

Percentage of patients with at least two points improvement in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.

Time frame:
Baseline, Day 15, Day 29
Reported as:
Count of participants · Participants
Percentage of Patients With at Least Two-point Improvement From Baseline in Clinical Status
ParticipantsRuxolitinib 5 mgPlacebo
Day 15206108
Day 29252129
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.647 · Odds ratio (or): 0.89 · 95% CI 0.55 to 1.46Comparison is ruxolitinib 5 mg/placebo. An odds ratio \> 1 favors the ruxolitinib 5 mg arm
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.997 · Odds ratio (or): 1.00 · 95% CI 0.52 to 1.92Comparison is ruxolitinib 5 mg/placebo. An odds ratio \> 1 favors the ruxolitinib 5 mg arm
SecondaryPercentage of Patients With at Least One-point Improvement From Baseline in Clinical Status

Percentage of patients with at least one point improvement in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.

Time frame:
Baseline, Day 15, Day 29
Reported as:
Count of participants · Participants
Percentage of Patients With at Least One-point Improvement From Baseline in Clinical Status
ParticipantsRuxolitinib 5 mgPlacebo
Day 15250128
Day 29261136
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.946 · Odds ratio (or): 0.98 · 95% CI 0.51 to 1.87Comparison is ruxolitinib 5 mg/placebo. An odds ratio \> 1 favors the ruxolitinib 5 mg arm
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.573 · Odds ratio (or): 0.79 · 95% CI 0.35 to 1.79Comparison is ruxolitinib 5 mg/placebo. An odds ratio \> 1 favors the ruxolitinib 5 mg arm
SecondaryPercentage of Patients With at Least One-point Deterioration From Baseline in Clinical Status

Percentage of patients with at least one point deterioration in clinical status on the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are treated as non-responders.

Time frame:
Baseline, Day 15, Day 29
Reported as:
Count of participants · Participants
Percentage of Patients With at Least One-point Deterioration From Baseline in Clinical Status
ParticipantsRuxolitinib 5 mgPlacebo
Day 15169
Day 29145
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.532 · Odds ratio (or): 0.75 · 95% CI 0.31 to 1.83Comparison is ruxolitinib 5 mg/placebo. An odds ratio \< 1 favors the ruxolitinib 5 mg arm
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.764 · Odds ratio (or): 1.18 · 95% CI 0.40 to 3.49Comparison is ruxolitinib 5 mg/placebo. An odds ratio \< 1 favors the ruxolitinib 5 mg arm
SecondaryTime to Improvement in Clinical Status

Time to improvement in clinical status from baseline category to one less severe category of the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Median time to improvement is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study. Patients who did not achieve improvement and did not die are censored at their last clinical status assessment date.

Time frame:
29 days
Reported as:
Median · days
Time to Improvement in Clinical Status
daysRuxolitinib 5 mgPlacebo
Time to Improvement in Clinical Status9.0 (8.0 to 10.0)9.0 (8.0 to 12.0)
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · Proportional hazards model · p = 0.330 · Hazard ratio (hr): 1.11 · 95% CI 0.90 to 1.37Between group comparison using competing risk framework. A hazard ratio \> 1 favors the ruxolitinib 5 mg arm
SecondaryMean Change From Baseline in the Clinical Status

Mean change from baseline in the 9-point ordinal scale. The baseline value of clinical status is defined as the last assessment prior to first dose of double-blind treatment. Patients with missing data at Day 15 and/or Day 29 are excluded from the analysis. A negative change from baseline in the clinical status is a favorable outcome.

Time frame:
Baseline, Day 15, Day 29
Reported as:
Least squares mean · score on scale
Mean Change From Baseline in the Clinical Status
score on scaleRuxolitinib 5 mgPlacebo
Day 15-1.96 ± 0.084-1.93 ± 0.118
Day 29-2.61 ± 0.090-2.69 ± 0.126
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · ANCOVA · p = 0.831 · Least squares (ls) mean: -0.03 · 95% CI -0.31 to 0.25
  • Ruxolitinib 5 mg vs Placebo · ANCOVA · p = 0.624 · Ls mean: 0.08 · 95% CI -0.23 to 0.38
SecondaryMortality Rate

Mortality rate is determined as the proportion of participants who died by study Day 15 and Day 29

Time frame:
Day 15, Day 29
Reported as:
Count of participants · Participants
Mortality Rate
ParticipantsRuxolitinib 5 mgPlacebo
Day 1562
Day 2993
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.944 · Odds ratio (or): 0.94 · 95% CI 0.20 to 5.57Comparison is ruxolitinib 5 mg/placebo. An odds ratio \< 1 favors the ruxolitinib 5 mg arm
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.775 · Odds ratio (or): 1.21 · 95% CI 0.35 to 5.11Comparison is ruxolitinib 5 mg/placebo. An odds ratio \< 1 favors the ruxolitinib 5 mg arm
SecondaryProportion of Patients Requiring Mechanical Ventilation

Proportion of patients requiring mechanical ventilation. Analyses are cumulative, thus analysis on Day 29 includes all events till that day. Patients who required mechanical ventilation at randomization are excluded from the analysis.

Time frame:
Day 1 - Day 29
Reported as:
Count of participants · Participants
Proportion of Patients Requiring Mechanical Ventilation
ParticipantsRuxolitinib 5 mgPlacebo
Proportion of Patients Requiring Mechanical Ventilation2210
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.987 · Odds ratio (or): 0.99 · 95% CI 0.45 to 2.21Comparison is ruxolitinib 5 mg/placebo. An odds ratio \< 1 favors the ruxolitinib 5 mg arm
SecondaryDuration of Hospitalization

Duration of hospitalization is defined as time to hospital discharge. Median time to hospital discharge is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study. Patients who were not discharged and did not die are censored at their last assessment date.

Time frame:
29 days
Reported as:
Median · days
Duration of Hospitalization
daysRuxolitinib 5 mgPlacebo
Duration of Hospitalization9.0 (8.0 to 10.0)9.0 (8.0 to 12.0)
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · Proportional hazards model · p = 0.738 · Hazard ratio (hr): 1.04 · 95% CI 0.84 to 1.28Between group comparison using competing risk framework. A hazard ratio \> 1 favors the ruxolitinib 5 mg arm
SecondaryTime to Hospital Discharge or to a NEWS2 Score of ≤2

The time to hospital discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours whichever comes first. The NEWS2 is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst). Median time is estimated by Kaplan-Meier method, with dead patients being censored at the maximum follow-up time in the study.

Time frame:
29 days
Reported as:
Median · days
Time to Hospital Discharge or to a NEWS2 Score of ≤2
daysRuxolitinib 5 mgPlacebo
Time to Hospital Discharge or to a NEWS2 Score of ≤24.0 (3.0 to 4.0)4.0 (3.0 to 5.0)
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · Proportional hazards model · p = 0.869 · Hazard ratio (hr): 1.02 · 95% CI 0.84 to 1.23Between group comparison using competing risk framework. A hazard ratio \> 1 favors the ruxolitinib 5 mg arm
SecondaryChange From Baseline in NEWS2 Score

The National Early Warning Score 2 (NEWS2) is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst). At each visit, only patients with a value at both baseline and the respective visit are included. A negative change from baseline in NEWS2 score is a favorable outcome.

Time frame:
Baseline, Days 3, 5, 8, 11, 15, and 29
Reported as:
Mean · score on scale
Change From Baseline in NEWS2 Score
score on scaleRuxolitinib 5 mgPlacebo
Day 3-0.7 ± 1.91-0.6 ± 2.13
Day 5-1.0 ± 2.02-0.8 ± 2.19
Day 8-1.3 ± 2.25-1.3 ± 2.60
Day 11-1.1 ± 2.70-1.3 ± 2.74
Day 15-1.9 ± 2.34-2.2 ± 2.35
Day 29-2.3 ± 2.37-2.5 ± 2.17
SecondaryChange From Baseline in SpO2/FiO2 Ratio

Change from baseline in peripheral oxygen saturation / fraction of inspired oxygen ratio (SpO2/FiO2 ratio). At each visit, only patients with a value at both baseline and the respective visit are included. A positive change from baseline in SpO2/FiO2 ratio is a favorable outcome.

Time frame:
Baseline, Day 15, Day 29
Reported as:
Mean · no units
Change From Baseline in SpO2/FiO2 Ratio
no unitsRuxolitinib 5 mgPlacebo
Day 1590.110 ± 104.4783106.766 ± 100.9778
Day 29105.553 ± 98.2452109.710 ± 95.4279
SecondaryProportion of Patients With no Oxygen Therapy

Proportion of patients with no oxygen therapy (defined as oxygen saturation ≥ 94% on room air) at Days 15 and 29. Analyses are cumulative, thus analysis on each day includes all events till that day. Patients with missing data at Day 15 and/or Day 29 are excluded from the analysis.

Time frame:
Day 15, Day 29
Reported as:
Count of participants · Participants
Proportion of Patients With no Oxygen Therapy
ParticipantsRuxolitinib 5 mgPlacebo
Day 15255133
Day 29262136
Statistical analysis
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · p = 0.325 · Odds ratio (or): 0.61 · 95% CI 0.23 to 1.63Comparison is ruxolitinib 5 mg/placebo. An odds ratio \> 1 favors the ruxolitinib 5 mg arm
  • Ruxolitinib 5 mg vs Placebo · Regression, Logistic · Odds ratio (or): 1.22 · 95% CI 0.25 to 5.40Comparison is ruxolitinib 5 mg/placebo. An odds ratio \> 1 favors the ruxolitinib 5 mg arm
Post-hocAll Collected Deaths

Deaths in the safety population were evaluated in all participants who received at least one dose of double-blind treatment. Total deaths were evaluated in all participants randomized.

Time frame:
29 days
Reported as:
Number · participants
All Collected Deaths
participantsRuxolitinib 5 mgPlacebo
Deaths in the safety population93
Total deaths93

Adverse events

Collected over From first dose of double-blind treatment and up to the last study visit (Day 29).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib 5 mg9/281 (3.2%)31/281 (11%)113/281 (40.2%)
Placebo3/143 (2.1%)15/143 (10.5%)62/143 (43.4%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventRuxolitinib 5 mgPlacebo
COVID-19Infections and infestations8/2813/143
HypoxiaRespiratory, thoracic and mediastinal disorders4/2814/143
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/2811/143
Respiratory failureRespiratory, thoracic and mediastinal disorders2/2812/143
PneumoniaInfections and infestations3/2810/143
Cardiopulmonary failureCardiac disorders0/2811/143
VertigoEar and labyrinth disorders0/2811/143
Multiple organ dysfunction syndromeGeneral disorders1/2811/143
Escherichia bacteraemiaInfections and infestations0/2811/143
Urinary tract infectionInfections and infestations0/2811/143
Most frequent other events
Showing 10 of 26
Most frequent other events
EventRuxolitinib 5 mgPlacebo
DiarrhoeaGastrointestinal disorders21/28112/143
HeadacheNervous system disorders23/28111/143
NauseaGastrointestinal disorders6/28111/143
Alanine aminotransferase increasedInvestigations17/2816/143
ConstipationGastrointestinal disorders9/2817/143
HypokalaemiaMetabolism and nutrition disorders8/2817/143
CoughRespiratory, thoracic and mediastinal disorders12/2813/143
HyperkalaemiaMetabolism and nutrition disorders6/2816/143
FatigueGeneral disorders10/2812/143
HyperglycaemiaMetabolism and nutrition disorders4/2815/143

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ruxolitinib 5 mgPlaceboTotal
Mean56.4 ± 13.756.9 ± 12.556.5 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib 5 mgPlaceboTotal
Female12572197
Male16273235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ruxolitinib 5 mgPlaceboTotal
White242109351
American Indian Or Alaska Native261339
Black Or African American6915
Asian5510
Multiple325
Unknown5712
08

Study locations

61 sites
  • Novartis Investigative Site
    Fullerton, California 92835, United States
  • Novartis Investigative Site
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    Denver, Colorado 80205, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30312, United States
  • Novartis Investigative Site
    Idaho Falls, Idaho 83404, United States
  • Novartis Investigative Site
    Ann Arbor, Michigan 48109, United States
  • Novartis Investigative Site
    Newark, New Jersey 07103, United States
  • Novartis Investigative Site
    Bronx, New York 10461, United States
  • Novartis Investigative Site
    Mesquite, Texas 75149, United States
  • Novartis Investigative Site
    Seattle, Washington 98104, United States
  • Novartis Investigative Site
    Madison, Wisconsin 53705-3611, United States
  • Novartis Investigative Site
    C A B A, Buenos Aires CP1405, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1426AAM, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1430BKC, Argentina
  • Novartis Investigative Site
    Rio de Janeiro, RJ 22640-000, Brazil
  • Novartis Investigative Site
    Blumenau, Santa Catarina 89030101, Brazil
  • Novartis Investigative Site
    Barretos, SP 14784 400, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 01327 001, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 04502 001, Brazil
  • Novartis Investigative Site
    Sorocaba, SP, Brazil
  • Novartis Investigative Site
    Rionegro, Antioquia 054047, Colombia
  • Novartis Investigative Site
    Barranquilla, Atlantico 080005, Colombia
  • Novartis Investigative Site
    Barranquilla, Colombia
  • Novartis Investigative Site
    Colombes Cedex, 92701, France
  • Novartis Investigative Site
    Eaubonne, 95600, France
  • Novartis Investigative Site
    Nantes Cedex 1, 44093, France
  • Novartis Investigative Site
    Pessac, 33604, France
  • Novartis Investigative Site
    Pierre Benite, 69495, France
  • Novartis Investigative Site
    Lubeck, 23538, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Nuernberg, 90419, Germany
  • Novartis Investigative Site
    México, Distrito Federal 14050, Mexico
  • Novartis Investigative Site
    Ciudad de Mexico, Mexico CP 14080, Mexico
  • Novartis Investigative Site
    Estado de Mexico, 52787, Mexico
  • Novartis Investigative Site
    San Isidro, Lima 27, Peru
  • Novartis Investigative Site
    San Miguel, Lima 32, Peru
  • Novartis Investigative Site
    Lima, 10, Peru
  • Novartis Investigative Site
    Lima, 1, Peru
  • Novartis Investigative Site
    Barnaul, 656045, Russian Federation
  • Novartis Investigative Site
    Moscow, 111539, Russian Federation
  • Novartis Investigative Site
    Moscow, 123056, Russian Federation
  • Novartis Investigative Site
    Ryazan, 390039, Russian Federation
  • Novartis Investigative Site
    S-Petersburg, 194354, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 194044, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 199106, Russian Federation
  • Novartis Investigative Site
    Sestroretsk, 197706, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 193312, Russian Federation
  • Novartis Investigative Site
    Salamanca, Castilla Y Leon 37007, Spain
  • Novartis Investigative Site
    Barcelona, Cataluna 08035, Spain
  • Novartis Investigative Site
    Badalona, Catalunya 08916, Spain
  • Novartis Investigative Site
    Madrid, 28031, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Istanbul, TUR 34098, Turkey
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Istanbul, Turkey
  • Novartis Investigative Site
    Yenisehir/Izmir, 35110, Turkey
  • Novartis Investigative Site
    Harrow, HA1 3UJ, United Kingdom
  • Novartis Investigative Site
    Leeds, LS9 7TF, United Kingdom
  • Novartis Investigative Site
    London, SE5 9RS, United Kingdom
  • Novartis Investigative Site
    London, WC1E 6HX, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9PL, United Kingdom
09

References and documents

Publications

  • Han MK, Antila M, Ficker JH, Gordeev I, Guerreros A, Bernus AL, Roquilly A, Sifuentes-Osornio J, Tabak F, Teijeiro R, Bandelli L, Bonagura DS, Shu X, Felser JM, Knorr B, Cao W, Langmuir P, Lehmann T, Levine M, Savic S. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Rheumatol. 2022 May;4(5):e351-e361. doi: 10.1016/S2665-9913(22)00044-3. Epub 2022 Mar 29. Erratum In: Lancet Rheumatol. 2024 Mar;6(3):e140. doi: 10.1016/S2665-9913(24)00032-8. PubMed 35368384 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Oct 2020, 5 months.

Results were first posted in Jun 2021, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2020
First posted
Apr 24, 2020
StartActual
May 2, 2020
Primary completionActual
Oct 17, 2020
CompletionActual
Oct 17, 2020
Results first posted
Jun 2, 2021
Last update
Oct 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04362137
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 24, 2020
Start date
May 2, 2020
Primary completion
Oct 17, 2020
Completion
Oct 17, 2020
Results posted
Jun 2, 2021
Last update
Oct 11, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion